InsuLine Medical
Insulin Treatment Method
Company Overview
Snapshot
Founded in February 2007 by Gabriel Bitton, InsuLine Medical operates with 1–10 employees. The company has raised $6.5 million across 4 funding rounds from 2 investors. In June 2019, InsuLine Medical was delisted from the TASE.
Business overview
InsuLine Medical is dedicated to enhancing current insulin treatment methods by leveraging human physiology. Its core product, the InsuPad, combines a disposable injection window with a reusable control unit that stabilizes skin conditions. By gently warming the skin, the device improves blood flow, facilitating faster and more effective insulin absorption. The InsuPad is a non-invasive, safe, and easy-to-use medical device with CE mark approval for the European Union, offering clinical benefits to patients, physicians, and health insurance providers. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Drug Delivery for chronic patients, particularly those with diabetes.
Strategic signal
In March 2016, InsuLine Medical signed a non-binding Memorandum of Understanding to distribute its InsuPad product in Brazil. This move signaled the company's intent to expand its market reach beyond its initial commercialization efforts in Germany and Israel, indicating a strategic focus on international growth and broader adoption of its insulin treatment technology.
Log in to access full profile ›Company Intelligence Q&A
- What is InsuLine Medical's primary product?
- InsuLine Medical's primary product is the InsuPad, a device designed to improve insulin absorption by gently warming the skin to increase blood flow at the injection site.
- When was InsuLine Medical founded?
- InsuLine Medical was founded in February 2007.
- What was a significant corporate event for InsuLine Medical in 2019?
- In June 2019, InsuLine Medical was delisted from the TASE, ceasing its operations.
- What was InsuLine Medical's total funding amount?
- InsuLine Medical has raised a total of $6.5 million across 4 funding rounds.
- What strategic partnership did InsuLine Medical form for commercialization?
- InsuLine Medical initiated commercialization in Germany in collaboration with J&J (LifeScan) and in Israel with DYN diagnostics.